Related Experiment Video
Updated: Apr 30, 2026
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
The effect of statins on cardiac allograft survival
1Department of Surgery, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
Insights
Statins improve survival after heart transplantation. This study found that patients taking statins had better long-term survival rates and fewer cardiac deaths post-transplant.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Statins possess lipid-lowering and anti-inflammatory properties.
- These properties may mitigate allograft dysfunction by preventing cardiac allograft vasculopathy (CAV) and modulating immune responses.
Purpose of the Study:
- To investigate the impact of statin use on cardiac allograft survival.
- The study was conducted at the National Taiwan University Hospital (NTUH).
Main Methods:
- Retrospective review of 168 heart transplant recipients at NTUH (2007-2012).
- Patients received standard immunosuppression and regular monitoring (biochemical, echocardiographic, and protocol biopsies).
- Patients were categorized into statin and non-statin groups.
Main Results:
- The overall 5-year survival rate was 79% ± 3%.
- Patients taking statins (57.4% of cohort) demonstrated significantly better 5-year survival and freedom from cardiac death (P < .01).
Conclusions:
- Statin therapy following heart transplantation is associated with improved patient survival.
- Statins may play a beneficial role in the long-term management of heart transplant recipients.
Purpose:
In addition to having a lipid-lowering effect, statins also have an anti-inflammatory effect that may reduce allograft dysfunction by preventing cardiac allograft vasculopathy (CAV) and play an immunomodulatory role. We studied the effect of statins on cardiac allograft survival at the National Taiwan University Hospital (NTUH).
Materials And Methods:
We retrospectively reviewed the patients undergoing heart transplantation at NTUH in the last 6 years. After transplantation, all patients received biochemical monitoring every month and echocardiographic examination regularly at NTUH. Protocol biopsy was performed in all except 18 pediatric patients. All patients received immunosuppressants, including tacrolimus or cyclosporine, everolimus or mycophenolate acid, and prednisolone. They were divided into statin and nonstatin groups according to whether or not a statin was taken.
Results:
At NTUH, from 2007 to 2012, 168 heart transplantations were performed. The ages of the patients ranged from 6 to 74 years old with male predominance. The etiology was mainly dilated cardiomyopathy (52.4%) and ischemic cardiomyopathy (39.3%), including 7 retransplantations from severe CAV with heart failure. Twenty-three patients (17%) suffered from acute rejection. The overall 1-year actuarial survival rate was 86% ± 2% and the 5-year survival rate was 79% ± 3%. Seventy-eight patients (57.4%) took statins and the statin group has a better 5-year survival rate and freedom from cardiac death survival rate (P < .01).
Conclusion:
Our study showed that the use of statins after transplantation was associated with better survival.
